We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has rejected Pain Therapeutics extended-release oxycodone Remoxy for the third time, issuing a complete response letter that hinges on the agency’s request for new studies to substantiate the product’s abuse-deterrence label claims. Read More
Alcon Pharmaceuticals is asking the FDA to apply stricter requirements on bioequivalence studies intended to supplement applications for Durezol and Ciprodex generics. Read More